05.27.15
Livingston, N.J.-based Milestone Scientific Inc.’s, a research and development company that develops injection technologies, has struck a deal with Italian specialty pharmaceutical company Fidia Farmaceutici SpA to co-develop and manufacture a custom intra-articular drug delivery instrument for Fidia’s hyaluronic acid formulations. Fidia makes hyaluronic acid formulations for joint pain.
Under the terms of the agreement, upon completion of Fidia’s evaluation of the technology, Milestone Scientific’s Epidural & IA (intra-articular) subsidiary and Fidia will develop a dedicated instrument and related disposables to optimize drug delivery and reduce pain associated with hyaluronic acid injections for joint pain. The custom instrument will be designed to deliver Fidia’s selected hyaluronic acid products exclusively.
“Fidia Farmaceutici’s focus on joint healthcare makes it an ideal partner for the intra-articular instrument, which has already received CE mark marketing clearance in Europe,” said CEO of Milestone Scientific Leonard Osser. “Fidia serves a large market and is one of the leading global manufacturers of hyaluronic acid formulations for intra-articular injections. Milestone’s patented technologies have already demonstrated the ability to deliver painless injections. We look forward to working with Fidia as we believe our instrument will prove equally beneficial in reducing or eliminating the pain associated with the delivery of hyaluronic acid into the joints.”
Under the terms of the agreement, upon completion of Fidia’s evaluation of the technology, Milestone Scientific’s Epidural & IA (intra-articular) subsidiary and Fidia will develop a dedicated instrument and related disposables to optimize drug delivery and reduce pain associated with hyaluronic acid injections for joint pain. The custom instrument will be designed to deliver Fidia’s selected hyaluronic acid products exclusively.
“Fidia Farmaceutici’s focus on joint healthcare makes it an ideal partner for the intra-articular instrument, which has already received CE mark marketing clearance in Europe,” said CEO of Milestone Scientific Leonard Osser. “Fidia serves a large market and is one of the leading global manufacturers of hyaluronic acid formulations for intra-articular injections. Milestone’s patented technologies have already demonstrated the ability to deliver painless injections. We look forward to working with Fidia as we believe our instrument will prove equally beneficial in reducing or eliminating the pain associated with the delivery of hyaluronic acid into the joints.”